March 14, 2018 / 8:51 PM / 8 months ago

BRIEF-Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/Ii Clinical Trial

March 14 (Reuters) - Solid Biosciences Inc:

* SOLID BIOSCIENCES ANNOUNCES CLINICAL HOLD ON SGT-001 PHASE I/II CLINICAL TRIAL FOR DUCHENNE MUSCULAR DYSTROPHY

* SOLID BIOSCIENCES - FIRST PATIENT DOSED IN CLINICAL TRIAL WAS NON-AMBULATORY ADOLESCENT WHO RECEIVED 5E13 VG/KG OF SGT-001 ON FEB. 14

* SOLID BIOSCIENCES - SEVERAL DAYS AFTER ADMINISTRATION PATIENT WAS HOSPITALIZED DUE TO LABORATORY FINDINGS THAT INCLUDED DECREASE IN PLATELET COUNT

* SOLID BIOSCIENCES INC - ‍SOLID REPORTED EVENT TO FDA AND, BECAUSE IT WAS UNEXPECTED, CLASSIFIED IT AS A SUSAR​

* SOLID BIOSCIENCES INC - ‍HAS HALTED ENROLLMENT AND DOSING IN IGNITE DMD AND IS AWAITING FORMAL CLINICAL HOLD LETTER FROM FDA​

* SOLID BIOSCIENCES - PATIENT DOSED IN SGT-001 TRIAL ALSO SHOWED REDUCTION IN RED BLOOD CELL COUNT AND EVIDENCE OF COMPLEMENT ACTIVATION

* SOLID BIOSCIENCES - PATIENT DOSED IN SGT-001 TRIAL SHOWED NO SIGNS OF COAGULOPATHY AND NO RELEVANT CHANGES FROM BASELINE IN LIVER FUNCTION TESTS

* SOLID BIOSCIENCES INC - ‍AFFECTED PATIENT RESPONDED WELL TO MEDICAL TREATMENT AND IS CURRENTLY ASYMPTOMATIC​ Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below